Above The Fold in Healthcare
The Front Page of Healthcare News on the Internet by C. Michael Gibson MD
Related Articles
Industry supports FDA’s draft guidance on weight management drugs, suggests some refinements | RAPS
The pharmaceutical industry generally supports draft guidance from the US Food and Drug Administration (FDA) on the development of drugs and biologics for weight reduction…
Danielle Belardo, M.D. (@daniellebelardomd) • Instagram reel
717 likes, 21 comments – daniellebelardomd on April 15, 2025: “When people believe that medications like GLP-1 receptor agonists are just an aesthetic weight loss…
Danielle Belardo, M.D. (@daniellebelardomd) • Instagram reel
359 likes, 0 comments – daniellebelardomd on April 16, 2025: “Recapping ACC 25 prevention trials with my friend and colleague, the incredible and brilliant Dr.…
A new type of antibiotic pill may treat drug-resistant gonorrhea. It could be available this year.
If approved, the medication, which is already used to treat urinary tract infections, could become the first new class of antibiotic for the STI in…
A new type of antibiotic pill may treat drug-resistant gonorrhea. It could be available this year.
If approved, the medication, which is already used to treat urinary tract infections, could become the first new class of antibiotic for the STI in…
Pfizer to discontinue its GLP-1 pill for obesity due to liver toxicity
Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat…
Vision impairment following glucagon-like peptide-1 receptor agonist use: is it harmful? – PubMed
Vision impairment following glucagon-like peptide-1 receptor agonist use: is it harmful?
Asperger’s Removal from DSM Sparks Debate on Autism Support
The removal of Asperger’s Syndrome from the Diagnostic and Statistical Manual of Mental Disorders (DSM) and its integration into the broader category of Autism Spectrum…
A new antifungal drug works in a surprising way
Mandimycin, which targets a different essential fungi cell resource than other antifungal drugs, should harm other cell types as collateral — but doesn’t.
Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial
Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that fell short of investors’ expectations.